Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN)

CUSIP: 92840H400

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock, par value $0.001 per share
Total 13F shares
14,875,235
Total 13F value
$29,750,933
Holder snapshot 6 visible 7 signals
Share change
-449,833
Put/Call ratio
53%
SEC-reported price per share
$2.00
Number of holders
50
Value change
-$917,939
Number of buys
22
Show 1 more signal
Number of sells
15
Security identity Who this page is about. 1 source field
Shares outstanding
41,041,331

Security key

92840H400

Report period

Q2 2025

Institutions

50

Top holders

10

VTGN full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 Vistagen Therapeutics, Inc. SEC filings Vistagen Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G 13F 3/4/5 Lead comparable stake: 10% 13D/G row: BIOTECHNOLOGY VALUE FUND L P Showing 1-6 of 15 holder rows.

Quick read

BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 10%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership Top 5
BIOTECHNOLOGY VALUE FUND L P 10%
TCG Crossover Management, LLC 6.5%
STEMPOINT CAPITAL LP 5.8%
Nantahala Capital Management, LLC 4.8%
VANGUARD GROUP INC 4.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
13D/G
10%
$7,217,318
3,084,324 shares
 $0 31 Dec 2024
TCG Crossover Management, LLC
13F
Company
13F
6.5%
$6,691,451
2,676,580 shares
 — 31 Mar 2025
STEMPOINT CAPITAL LP
13F
Company
13F
5.8%
$5,111,689
2,366,554 shares
 — 31 Mar 2025
Nantahala Capital Management, LLC
13F
Company
13F
4.8%
$4,946,230
1,978,492 shares
 — 31 Mar 2025
VANGUARD GROUP INC
13F
Company
13F
4.8%
$4,900,431
1,960,172 shares
 — 31 Mar 2025
Commodore Capital LP
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
3.8%
$3,937,500
1,575,000 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
50
Shares
14,875,235
Rows available
50
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
47
Q2 2025 holders
50
Holder diff
3
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .